Partner
AL ZAHRAWI MEDICAL SUPPLIES, LLC
Invivoscribe lists AL ZAHRAWI MEDICAL SUPPLIES, LLC in its distributor directory for Oman.
Loading
Loading
Search products, companies, tests, and guides — go from query to quote request in one place.
Partner
Invivoscribe lists AL ZAHRAWI MEDICAL SUPPLIES, LLC in its distributor directory for Oman.
Technology
Comparative genomic hybridization (CGH) is a technique that allows the detection of losses and gains in DNA copy number across the entire genome without prior knowledge of specific chromosomal abnormalities. Comparative genomic hybridization utilizes the hybridization of differentially labeled tumor and reference DNA to generate a map of DNA copy number changes in tumor genomes. Comparative genomic hybridization is an ideal tool for analyzing chromosomal imbalances in archived tumor material and for examining possible correlations between these findings and tumor phenotypes. (from Ried et al. J Mol Med 1997 75:801-14)
Technology
A novel karyotyping procedure which is based on the simultaneous hybridization of 24 chromosome-specific painting probes labeled with different fluorochromes or fluorochrome combinations. The measurement of defined emission spectra by means of interferometer-based spectral imaging allows for the definitive discernment of all human chromosomes in different colors. (from Schrock et al., Hum Genet 1997:101:255-62)
Partner
DiaSys lists Al Zahrawi Qatar in its distributor directory for Qatar.
Partner
GeneProof lists Al-Faiha scientific Co. for laboratory and medical appliances in its distributor directory for Iraq.
Indicators
A metallic element in the boron group with atomic symbol Al, atomic number 13, and atomic weight 27.
Partner
GeneProof lists Hamad Saleh Al.Homaizi Grandsons Pharmaceutical Co WLL in its distributor directory for Kuwait.
Article
Research record from Clin Lab, 2026-10-01. PMID 42847947.
Tests
A two-staged test with purified coagulation factors in the first stage, and a FXa-specific chromogenic substrate in the second stage. In the first stage, diluted sample plasma, which has been treated with Al(OH)3 to remove prothrombin, is mixed with a combined reagent (human serum, factor V, phospholipids and calcium). In the second stage, a subsample from the first stage is mixed with normal plasma, providing prothrombin and fibrinogen, and the clotting time is measured to deduce the amount of FVIII present.